- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02152280
A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke
Research topic.
- A clinical trial of Danhong injection in treating acute ischemic stroke .
Research purpose.
- To evaluate the efficacy and safety of Danhong injection in treating acute ischemic stroke by a randomized, double-blind, multi-center, placebo-controlled clinical trial.
Research design.
- A randomized, double-blind, multi-center, placebo-controlled clinical trial.
Subject crowd.
- Accord with standard of western medicine diagnosis of acute cerebral infarction, stroke and blood stasis type of traditional Chinese medicine syndrome differentiation.
Sample size. - Total sample size of 320 patients, experimental group, control group is equal to 1 to 1.
Interim analysis.
- Interim analysis will be performed when the total number of included patients up to half of the sample size ,160 cases, and according to the interim analysis results to estimate the sample size and adjust the project adaptively.
Course of treatment.
- 10 days.
Research endpoint.
- The 90th day after the medication for the first time.
Observation index.
- General condition; the physical and chemical inspection related;
- Efficacy check : mRS, BI, NIHSS;
- Safety check: blood routine, urine routine, stool OB, liver function(ALT、AST), renal function (BUN, Cr), coagulation four indices(PT、APTT、TT、FIB), electrocardiogram.
Efficacy evaluation. 1. The main efficacy index: a. Percentage comparisons of two group patients of modified Rankin 0-2 grades on the 90th day.
Statistical analysis technique.
- Statistical analysis using SAS 9.2 system, all the statistical test adopted bilateral inspection, P value less than or equal to 0.05 will be considered a statistically significant difference.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Research topic. - A clinical trial of Danhong injection in treating acute ischemic stroke .
Research purpose.
- To evaluate the efficacy and safety of Danhong injection in treating acute ischemic stroke by a randomized, double-blind, multi-center, placebo-controlled clinical trial.
Research design. - A randomized, double-blind, multi-center, placebo-controlled clinical trial.
Subject crowd. - Accord with standard of western medicine diagnosis of acute cerebral infarction, stroke and blood stasis type of traditional Chinese medicine syndrome differentiation.
Sample size.
- Total sample size of 320 patients, experimental group, control group is equal to 1 to 1.
Interim analysis.
- Interim analysis will be performed when the total number of included patients up to half of the sample size ,160 cases, and according to the interim analysis results to estimate the sample size and adjust the project adaptively.
Inclusion criteria.
- Accord with the diagnostic criteria of cerebral infarction of "Guide of diagnosis and treatment of acute ischemic stroke in China" in 2010, and in the acute stage;
- Accord with the stroke and blood stasis type;
- Onset of acute ischemic stroke within 72 hours;
- NIHSS grade ≥ 4;
- Age ≥ 18;
- signed the inform consent form.
Exclusion criteria.
- Diagnosed with bleeding or other pathological brain disorders according to CT or MRI at baseline , such as vascular malformation, tumor, abscess or other common non ischemic cerebral disease (for multiple sclerosis);
- Patients with hrombolysis or endovascular treatment;
- Allergic constitution; the test drug allergy or its ingredients or elements allergy;
- With severe liver function damage(ALT and AST level more than 1.5 times higher than normal);
- With severe renal impairment (more than 1.5 times higher than normal amount of serum creatinine);
- With severe cardiac insufficiency (cardiac function rating level III above);
- Disabled patients of law (blind, deaf, dumb, mental retardation, mental disorder and physical disabilities caused by other reasons which affects the nerve function defect evaluation);
- With bleeding tendency or had serious bleeding within 3 months;
- Doubted or had alcohol and drug abuse history; Or who will lower the possibilities of enrollment or complicate the enrollment according to the investigaters' judgement;
- Menstrual period women, pregnant women and lactating women, pregnancy test positive or recent family planning;
Who being in other clinical trials or had finished other clinical trials within 3 months.
Dosage regimen.
1. Experimental group: Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days; 2. Control group : 0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
Course of treatment.
- 10 days.
Research endpoint.
- The 90th day after the medication for the first time.
Observation index.
- General condition; the physical and chemical inspection related;
- Efficacy check : mRS, BI, NIHSS;
- Safety check: blood routine, urine routine, stool OB, liver function(ALT、AST), renal function (BUN, Cr), coagulation four indices(PT、APTT、TT、FIB), electrocardiogram.
Observation point.
- The physical and chemical inspection related and electrocardiogram observed at the enrollment time;
- General condition and efficacy index observed on the 10th ,90th after the medication for the first time;
- Safety index observed on the 10th after the medication for the first time.
Efficacy evaluation.
The main efficacy index:
- Percentage comparisons of two group patients of modified Rankin 0-2 grades on the 90th day.
The secondary efficacy index:
- Mortality comparisons of two group patients on the 90th day;
- Percentage comparisons of two group patients of BI≥75 on the 90th day;
- NIHSS difference comparisons of two group on the 90th day;
- The proportion of new vascular events within 3 months (Ischemic stroke/hemorrhagic stroke/TIA/MI/vascular death).
Safety evaluation.
- All-Cause mortality within 90 days :the death toll of all cause within 90 days/ the total number of each group × 100%;
- Incidence of serious bleeding events (GUSTO definition, appendix 4), including fatal bleeding and symptomatic intracranial bleeding;
- Incidence of moderate bleeding events (GUSTO definition, appendix 4);
- Adverse events and serious adverse events reported by investigaters.
Statistical analysis technique.
- Statistical analysis using SAS 9.2 system, all the statistical test adopted bilateral inspection, P value less than or equal to 0.05 will be considered a statistically significant difference.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Accord with the diagnostic criteria of cerebral infarction of "Guide of diagnosis and treatment of acute ischemic stroke in China" in 2010, and in the acute stage;
- Accord with the stroke and blood stasis type;
- Onset of acute ischemic stroke within 72 hours;
- NIHSS grade ≥ 4;
- Age ≥ 18;
- signed the inform consent form.
Exclusion Criteria:
- Diagnosed with bleeding or other pathological brain disorders according to CT or MRI at baseline , such as vascular malformation, tumor, abscess or other common non ischemic cerebral disease (for multiple sclerosis);
- Patients with hrombolysis or endovascular treatment;
- Allergic constitution; the test drug allergy or its ingredients or elements allergy;
- With severe liver function damage(ALT and AST level more than 1.5 times higher than normal);
- With severe renal impairment (more than 1.5 times higher than normal amount of serum creatinine);
- With severe cardiac insufficiency (cardiac function rating level III above)
- Disabled patients of law (blind, deaf, dumb, mental retardation, mental disorder and physical disabilities caused by other reasons which affects the nerve function defect evaluation);
- With bleeding tendency or had serious bleeding within 3 months;
- Doubted or had alcohol and drug abuse history; Or who will lower the possibilities of enrollment or complicate the enrollment according to the investigaters' judgement;
- Menstrual period women, pregnant women and lactating women, pregnancy test positive or recent family planning;
- Who being in other clinical trials or had finished other clinical trials within 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Danhong Injection
Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
|
Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
|
Placebo Comparator: Normal Saline
0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
|
0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage comparisons of two groups of patients on the modified Rankin Scale 0-2 grades on the 90th day.
Time Frame: 0-90 day
|
Percentage comparisons of two groups of patients on the modified Rankin Scale 0-2 grades on the 90th day.
|
0-90 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fang D Cai, doctor, Traditional Chinese medicine department of Zhongshan Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V2.0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Danhong Injection
-
Beijing Bozhiyin T&S Co., Ltd.Unknown
-
China Academy of Chinese Medical SciencesChina Food and Drug AdministrationCompleted
-
China Academy of Chinese Medical SciencesChina Food and Drug AdministrationCompleted
-
China Academy of Chinese Medical SciencesChina Food and Drug AdministrationCompleted
-
China Academy of Chinese Medical SciencesChina Food and Drug AdministrationCompleted
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina